Mpox, driven by the monkeypox virus (MPXV), is rapidly evolving beyond its African roots, with Clade IIb driving global outbreaks and Clade I now spreading outside endemic regions. In August 2024, the WHO declared mpox a Public Health Emergency of International Concern, highlighting its escalating threat. While two FDA-approved vaccines—Jynneos™ and ACAM2000®—are available, uptake remains limited among high-risk populations. Alarmingly, new evidence shows Tecovirimat’s reduced efficacy against Clade I infections and the emergence of resistant mutations, leaving clinicians with few reliable therapeutic tools.
WHO’s approval of the Alinity m MPXV assay marks a pivotal step toward scaling diagnostic capacity, but access gaps remain a major barrier. Are you ready to rethink your mpox management strategies before resistance spreads further? Click here to read more How would you adapt…
